SCHEMBL650337

SCHEMBL650337

O=C(O)CCC(=O)Nc1ncc(/C=C2\S/C(=N\c3ccc(Cl)c(Cl)c3)NC2=O)s1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.50
MEN1 O00255 6/20 0.50
MAPT P10636 4/20 0.50
PLA2G1B P04054 1/20 0.50
ATG4B Q9Y4P1 1/20 0.50
PTPN7 P35236 4/20 0.44
PTPN12 Q05209 4/20 0.44
PTPN22 Q9Y2R2 4/20 0.44
DUSP3 P51452 3/20 0.44
PTGS2 P35354 1/20 0.41
POLB P06746 6/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CDC25A P30304 2/20 0.39
CDC25B P30305 2/20 0.39
LMNA P02545 1/20 0.38
PTPN5 P54829 1/20 0.38
PTPN11 Q06124 1/20 0.38
PSMD14 O00487 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL650338 1.00 KMT2A (0.50) KMT2AMEN1MAPTPLA2G1BATG4B
SCHEMBL13091415 0.89 PTPN11 (0.42) KMT2AMEN1MAPTPTPN7PTPN12
SCHEMBL652059 0.88 RNASEL (0.40) KMT2AMEN1MAPTPLA2G1BATG4B
SCHEMBL651036 0.88 RNASEL (0.40) KMT2AMEN1MAPTPLA2G1BATG4B
SCHEMBL650807 0.88 SYK (0.48) KMT2AMEN1MAPTPTPN7PTPN12
SCHEMBL649726 0.88 SYK (0.48) KMT2AMEN1MAPTPTPN7PTPN12
SCHEMBL653261 0.88 NPC1 (0.50) KMT2AMEN1MAPTPTPN7PTPN12
SCHEMBL653260 0.88 NPC1 (0.50) KMT2AMEN1MAPTPTPN7PTPN12
SCHEMBL652616 0.87 PTPN7 (0.49) KMT2AMEN1MAPTPTPN7PTPN12
SCHEMBL10176312 0.87 PTPN7 (0.49) KMT2AMEN1MAPTPTPN7PTPN12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2423204-A1 THIAZOLIDINONE DERIVATIVE SBI Biotech Co., Ltd. (JP) 2012-02-29 EP disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed
WO-2010122979-A1 THIAZOLIDINONE DERIVATIVE SBIバイオテック株式会社 (JP) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE CDC7, CDK17, CDCA2 KMT2A 3437/4885MEN1 1406/4885MAPT 3657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.